Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
Early studies on cell cycle regulation were based on experiments in model systems (Yeast, Xenopus, Starfish, Drosophila) and have shaped the way we understand many events that control the cell cycle. Although these model systems are of great value, the last decade was highlighted by studies done in human cells and using in vivo mouse models. Mouse models are irreplaceable tools for understanding the genetics, development, and survival strategies of mammals. New developments in generating targeting vectors and mutant mice have improved our approaches to study cell cycle regulation and cancer. Here we summarize the most recent advances of mouse model approaches in dissecting the mechanisms of cell cycle regulation and the relevance to human disease.
Aleem,
Mouse models of cell cycle regulators: new paradigms.
2006, Pubmed
Aleem,
Mouse models of cell cycle regulators: new paradigms.
2006,
Pubmed
Artus,
The cell cycle of early mammalian embryos: lessons from genetic mouse models.
2006,
Pubmed
Berthet,
Cdk2 and Cdk4 cooperatively control the expression of Cdc2.
2006,
Pubmed
Berthet,
Cdk2 knockout mice are viable.
2003,
Pubmed
Buchholz,
Different thermostabilities of FLP and Cre recombinases: implications for applied site-specific recombination.
1996,
Pubmed
Buchholz,
Improved properties of FLP recombinase evolved by cycling mutagenesis.
1998,
Pubmed
Capecchi,
Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century.
2005,
Pubmed
Carthon,
Genetic replacement of cyclin D1 function in mouse development by cyclin D2.
2005,
Pubmed
Christophorou,
Temporal dissection of p53 function in vitro and in vivo.
2005,
Pubmed
Ciemerych,
Cell cycle in mouse development.
2005,
Pubmed
Copeland,
Recombineering: a powerful new tool for mouse functional genomics.
2001,
Pubmed
Court,
Mini-lambda: a tractable system for chromosome and BAC engineering.
2003,
Pubmed
Dankort,
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
2009,
Pubmed
Dankort,
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
2007,
Pubmed
Datta,
A set of recombineering plasmids for gram-negative bacteria.
2006,
Pubmed
Dickins,
Tissue-specific and reversible RNA interference in transgenic mice.
2007,
Pubmed
Fisher,
A single fission yeast mitotic cyclin B p34cdc2 kinase promotes both S-phase and mitosis in the absence of G1 cyclins.
1996,
Pubmed
Frescas,
Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer.
2008,
Pubmed
Geng,
Rescue of cyclin D1 deficiency by knockin cyclin E.
1999,
Pubmed
Gingrich,
Inducible gene expression in the nervous system of transgenic mice.
1998,
Pubmed
Gossen,
Transcriptional activation by tetracyclines in mammalian cells.
1995,
Pubmed
Gossen,
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
1992,
Pubmed
Hartwell,
Genetic control of the cell-division cycle in yeast. I. Detection of mutants.
1970,
Pubmed
Hochegger,
Cyclin-dependent kinases and cell-cycle transitions: does one fit all?
2008,
Pubmed
Jonkers,
Conditional mouse models of sporadic cancer.
2002,
Pubmed
Kolb,
Genome engineering using site-specific recombinases.
2002,
Pubmed
Lee,
Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human.
2006,
Pubmed
Lee,
A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA.
2001,
Pubmed
Lewandoski,
Conditional control of gene expression in the mouse.
2001,
Pubmed
Li,
Rb/Cdk2/Cdk4 triple mutant mice elicit an alternative mechanism for regulation of the G1/S transition.
2009,
Pubmed
Malumbres,
Cell cycle kinases in cancer.
2007,
Pubmed
Malumbres,
Cell cycle, CDKs and cancer: a changing paradigm.
2009,
Pubmed
Matzuk,
The biology of infertility: research advances and clinical challenges.
2008,
Pubmed
Morgan,
Cyclin-dependent kinases: engines, clocks, and microprocessors.
1997,
Pubmed
Müller,
Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis.
1999,
Pubmed
Murata,
ang is a novel gene expressed in early neuroectoderm, but its null mutant exhibits no obvious phenotype.
2004,
Pubmed
Murphy,
Use of bacteriophage lambda recombination functions to promote gene replacement in Escherichia coli.
1998,
Pubmed
Nagy,
Cre recombinase: the universal reagent for genome tailoring.
2000,
Pubmed
Nakayama,
Ubiquitin ligases: cell-cycle control and cancer.
2006,
Pubmed
Nurse,
Genetic control of the cell division cycle in the fission yeast Schizosaccharomyces pombe.
1976,
Pubmed
Orford,
Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation.
2008,
Pubmed
Ortega,
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice.
2003,
Pubmed
Padmakumar,
Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53.
2009,
Pubmed
Pelengaris,
Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression.
2002,
Pubmed
Rane,
Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence.
2002,
Pubmed
Rane,
Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia.
1999,
Pubmed
Sage,
Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.
2003,
Pubmed
Santamaria,
Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
2006,
Pubmed
Santamaría,
Cdk1 is sufficient to drive the mammalian cell cycle.
2007,
Pubmed
Satyanarayana,
Genetic substitution of Cdk1 by Cdk2 leads to embryonic lethality and loss of meiotic function of Cdk2.
2008,
Pubmed
Sharan,
Recombineering: a homologous recombination-based method of genetic engineering.
2009,
Pubmed
Sherr,
CDK inhibitors: positive and negative regulators of G1-phase progression.
1999,
Pubmed
Sherr,
Living with or without cyclins and cyclin-dependent kinases.
2004,
Pubmed
Shizuya,
Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector.
1992,
Pubmed
Sotillo,
Invasive melanoma in Cdk4-targeted mice.
2001,
Pubmed
Sotillo,
Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors.
2001,
Pubmed
Susaki,
Common and specific roles of the related CDK inhibitors p27 and p57 revealed by a knock-in mouse model.
2009,
Pubmed
Van Dyke,
Cancer modeling in the modern era: progress and challenges.
2002,
Pubmed
van Leuken,
To cell cycle, swing the APC/C.
2008,
Pubmed
Ventura,
Restoration of p53 function leads to tumour regression in vivo.
2007,
Pubmed
Waterston,
Initial sequencing and comparative analysis of the mouse genome.
2002,
Pubmed
Wu,
A protocol for constructing gene targeting vectors: generating knockout mice for the cadherin family and beyond.
2008,
Pubmed
Yu,
An efficient recombination system for chromosome engineering in Escherichia coli.
2000,
Pubmed
Zhang,
A new logic for DNA engineering using recombination in Escherichia coli.
1998,
Pubmed
Zhao,
Mouse BAC ends quality assessment and sequence analyses.
2001,
Pubmed